Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-24

Study Completion Date

2028-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Long-term follow-up is designed to evaluate the safety of patient with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Follow-up Study of Livercellgram in Alcoholic LC Patients Who Completed Livercellgram Phase 2 Study

NCT02806011

Alcoholic Liver Cirrhosis

COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis

NCT04689152

Alcoholic Cirrhosis

RECRUITING PHASE3

REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)

NCT01875081

Alcoholic Liver Cirrhosis

COMPLETED PHASE2

Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis

NCT01503749

Liver Cirrhosis

COMPLETED PHASE1

2-Week Study In People With Nonalcoholic Fatty Liver Disease

NCT03513588

Non-alcoholic Steatohepatitis Non-alcoholic Fatty Liver Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate the safety for 60 months after a single dose of Cellgram-LC in patients with alcoholic liver cirrhosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcoholic Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cellgram-LC

Patients with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.

Group Type EXPERIMENTAL

Cellgram-LC

Intervention Type BIOLOGICAL

Patients who had administered Cellgram-LC in PMC-P-07 study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cellgram-LC

Patients who had administered Cellgram-LC in PMC-P-07 study

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Those who participated in PMC-P-07 clinical trials and received Cellgram-LC
2. Those who voluntarily agreed in writing to participate in this investigation